In a large PPMS population that included older patients and people with more advanced disease, ocrelizumab led to a 30% risk ...

Already approved for progressive multiple sclerosis, ocrelizumab in a second phase 3 study demonstrates meaningful clinical ...

Ocrelizumab is noninferior to fingolimod, demonstrating efficacy and safety in children and adolescents with ...

During year 6 of continuous treatment with BRIUMVI the annualized relapse rate was 0.012, equivalent to one relapse occurring every 83 years of ...

Data at ECTRIMS will help back fenebrutinib as a potential addition to Roche’s arsenal of drugs, and help cement Ocrevus’s ...

In this clip, Kathy Oubre, MS, CEO of Pontchartrain Cancer Center, highlights the biggest opportunities for expanding cancer ...

The blogger Trevis Gleason explores long-term effects of corticosteroid use in managing multiple sclerosis, and what everyone with MS should know.

Ocrevus subcutaneous maintains consistent benefit-risk profile after two years -- New late-breaking data confirms Ocrevus ...

Currently, seven CAR T-cell therapies 1 and six T-cell engager therapies have been approved by the FDA. 2 Despite these advancements and their clear benefits, immunotherapy-based treatments carry ...

OCREVUS subcutaneous maintains consistent benefit-risk profile after two years New late-breaking data confirms OCREVUS ...